Ketamine in Palliative and End-of-Life Care

Ketamine in palliative and end-of-life care addresses two separate problems at once: pain that no longer responds well to opioids, and the existential distress that comes with facing death. Advanced cancer, organ failure, and progressive neurological disease often produce pain with nociceptive, neuropathic, and central sensitization components that standard opioid regimens cannot fully control. At the same time, many patients face anxiety, depression, loss of meaning, and fear that standard antidepressants and anxiolytics are too slow to relieve given a limited prognosis. Ketamine's action at the NMDA receptor gives it a role in both areas, which is why palliative care teams increasingly consider it and why some hospice programs use it in select cases. For general dosing context on the sublingual route, see our sublingual ketamine therapy guide.

Managing Opioid-Refractory Pain

As disease progresses and opioid requirements climb, opioid-induced hyperalgesia can paradoxically make pain worse instead of better. Ketamine's NMDA receptor blockade targets the central sensitization and neuropathic components that opioids handle poorly, and it can reverse opioid-induced hyperalgesia in a way that sometimes allows the opioid dose to come down while pain control improves. According to the StatPearls clinical reference on ketamine, NMDA antagonism is the primary mechanism behind both its analgesic and dissociative effects.

Clinical experience in palliative settings supports the mechanism: studies report meaningful pain reduction in 50 to 70 percent of patients with opioid-refractory cancer pain, and neuropathic cancer pain, one of the hardest pain types to treat, tends to respond particularly well to ketamine.

Dosing for Palliative Pain

Inpatient palliative care often relies on continuous low-dose ketamine infusions, but oral and sublingual troches have a place for ambulatory patients still managing pain from home. A typical low-dose range is 50 to 150 mg, taken one to three times daily for analgesic maintenance. This sub-dissociative dosing provides meaningful relief without significantly impairing daily function. As mobility declines or a patient moves into hospice care, the route often shifts to continuous subcutaneous infusion, a transition our troche versus infusion comparison covers in more general terms.

Existential Distress at the End of Life

Physical pain is only part of what patients face. According to the World Health Organization's depression fact sheet, depression is a leading contributor to disease burden worldwide, and among patients with advanced cancer specifically, published estimates put the rate at 25 to 40 percent. Beyond depression, terminally ill patients commonly describe pervasive anxiety about dying, demoralization and loss of meaning, unresolved relationships or unfinished business, and fear of nonexistence itself. These experiences erode both quality of life and quality of dying. The National Institute of Mental Health notes that conventional antidepressants can take weeks to reach full effect, a timeline that does not fit every palliative situation.

Ketamine's Rapid Psychological Effects

Ketamine's fast-acting antidepressant and anxiolytic effects, combined with its dissociative properties at therapeutic doses, have drawn interest as a way to address existential distress directly. At higher, session-based doses, patients often describe a softening of ego-driven fear and a shift in perspective on their circumstances. Researchers studying psilocybin-assisted therapy for end-of-life distress at Johns Hopkins and NYU have reported that mystical-type experiences reduce death anxiety and depression in ways that last well beyond the session itself. Ketamine's dissociative state shares some features with that experience, including reduced attachment to ordinary self-focus, though the two drugs work through different pharmacological pathways. Case reports and small studies suggest ketamine sessions can reduce existential distress, death anxiety, and demoralization in terminally ill patients, but the evidence base remains limited in size even where the underlying rationale is coherent. For related research, see our coverage of treatment-resistant depression ketamine troche options.

Protocol Patterns and Adjusting for Prognosis

Palliative teams often combine two dosing patterns: low-dose analgesic troches of 50 to 100 mg, taken daily or as needed for breakthrough pain, and moderate-dose session troches of 150 to 250 mg, used once every one to four weeks with skilled psychological support for existential distress. As disease progresses, the emphasis usually shifts. Early on, ketamine may be one part of a multimodal pain and psychological management plan. As functional status declines, regimens tend to simplify. In the final weeks, ketamine may move to continuous subcutaneous infusion or be discontinued in favor of palliative sedation, depending on the patient's goals of care. Our troche safety guide covers general monitoring practices that apply across these phases.

Family members and caregivers supporting a patient using ketamine at home need practical preparation: understanding what a session involves, staying calm and present during it, knowing basic safety steps such as keeping the patient in a safe position, and having a direct line to the palliative care team for questions.

Dignity, Autonomy, and Finding a Qualified Provider

For patients facing a terminal diagnosis, ketamine's capacity to produce moments of calm, expanded perspective, or a sense of transcendence has value beyond symptom control. Many palliative care ethicists frame this as part of dying with dignity, giving patients access to meaningful psychological experiences in their remaining time rather than treating comfort as an afterthought.

Not every palliative care provider is trained in ketamine prescribing, and not every ketamine prescriber has palliative care experience. Patients and families considering this option should look for a provider or team with background in both. Our guide on working with your provider outlines questions to raise during that search. Palliative care organizations are publishing more educational material on ketamine as clinical familiarity grows, which should make finding an experienced provider easier over time.

Sources

StatPearls: Ketamine, National Library of Medicine. PubChem: Ketamine Compound Summary, National Center for Biotechnology Information. MedlinePlus: Ketamine Injection, National Library of Medicine. NIMH: Depression, National Institute of Mental Health. WHO: Depression Fact Sheet, World Health Organization.